Disease · MONDO_0006837

low tension glaucoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. low tension glaucoma. Diseases, record MONDO_0006837. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006837

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: low tension glaucoma; Open Targets
Open Targets ID: MONDO_0006837; Open Targets
Other names: normal tension glaucoma; Open Targets
Disease Ontology: DOID:13544; Disease Ontology
MeSH: D057066; MeSH
Highest stage of its drugs: Phase 2, for 4 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DORZOLAMIDE	CHEMBL218490	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AMA0076	CHEMBL3545073		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TIMOLOL	CHEMBL499	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TIMOLOL MALEATE	CHEMBL1200870	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BRIMONIDINE	CHEMBL844	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
LATANOPROST	CHEMBL1051	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets9

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Beta-1 adrenergic receptor	2	Beta-1 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	2	Beta-2 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Unknown	https://conductscience.org/library/genes/152	Drugs and targets
CA2	Carbonic anhydrase 2	1	Carbonic anhydrase II inhibitor	Phase 2	https://conductscience.org/library/genes/760	Drugs and targets
PTGFR	Prostaglandin F2-alpha receptor	1	Prostanoid FP receptor agonist	Unknown	https://conductscience.org/library/genes/5737	Drugs and targets
ROCK1	Rho-associated protein kinase	1	Rho-associated protein kinase inhibitor	Phase 2	https://conductscience.org/library/genes/6093	Drugs and targets
ROCK2	Rho-associated protein kinase	1	Rho-associated protein kinase inhibitor	Phase 2	https://conductscience.org/library/genes/9475	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01105065	Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma	Not applicable	46	2016-10-27	Glaucoma	BRIMONIDINE	Its record names the disease	ClinicalTrials.gov
NCT01175902	Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma	Not applicable	44	2014-12-12	Normal Tension Glaucoma	DORZOLAMIDE, LATANOPROST	Its record names the disease	ClinicalTrials.gov
NCT00832377	COSOPT (Timolol/Dorzolamide Combination) Normal Tension Glaucoma Study (MK0507A-161)(COMPLETED)	Phase 2	37	2011-03-24	Glaucoma	DORZOLAMIDE, TIMOLOL	Its record names the disease	ClinicalTrials.gov
NCT03106532	Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma	Phase 2	119		Normal Tension Glaucoma	AMA0076	Its record names the disease	ClinicalTrials.gov
NCT06030193	Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)	Phase 2	37		Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye, Glaucoma	TIMOLOL MALEATE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Latanoprost vs Dorzolamide/Timolol: serious adverse events	0 of 44	0 of 44	88	NCT01175902

Source Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23377586	RESULT	1	PubMed
26756747	DERIVED	1	PubMed
24709811	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006837

GET https://conductscience.org/api/diseases/v1/MONDO_0006837/drugs

API reference For AI assistants